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Introduction: ES-62, a phosphorylcholine (PC)-containing immunomodulator secreted by the
parasitic worm Acanthocheilonema viteae, protects against nephritis in the MRL/Lpr mouse
model of systemic lupus erythematosus (SLE). However, ES-62 is not suitable for development
as a therapy and thus we have designed drug-like small molecule analogues (SMAs) based
around its active PC-moiety. To provide proof of concept that ES-62-based SMAs exhibit
therapeutic potential in SLE, we have investigated the capacity of two SMAs to
protect against nephritis when administered to MRL/Lpr mice after onset of kidney
damage. Methods: SMAs 11a and 12b were evaluated for their ability to suppress antinuclear
antibody (ANA) generation and consequent kidney pathology in MRL/Lpr mice when admin-
istered after the onset of proteinuria. Results: SMAs 11a and 12b suppressed development of
ANA and proteinuria. Protection reflected downregulation of MyD88 expression by kidney
cells and this was associated with reduced production of IL-6, a cytokine that exhibits promise
as a therapeutic target for this condition. Conclusions: SMAs 11a and 12b provide proof of
principle that synthetic compounds based on the safe immunomodulatory mechanisms of
parasitic worms can exhibit therapeutic potential as a novel class of drugs for SLE, a disease
for which current therapies remain inadequate. Lupus (2015) 0, 1–6.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease in which inflammation and
organ damage is driven by the deposition of anti-
nuclear antibody (ANA)-containing immune com-
plexes, with glomerulonephritis a major cause
of morbidity. Despite recent advances in B cell-
targeting therapies, there remains urgent need
for safer, non-immunosuppressive therapies.1
Increasing epidemiological evidence that infection
with parasitic helminths can protect against allergic
and autoimmune inflammatory disorders has led to
clinical trials that suggest that ‘worm therapy’
shows promise in the treatment of inflammatory
conditions.2 Moreover, characterization of the
actions of helminth-derived immunomodulators in
preventing development of inflammatory disorders
in experimental models has facilitated the identifi-
cation of potential novel drug targets.3 Consistent
with these advances, we have recently shown that
prophylactic administration of ES-62, an immuno-
modulator secreted by the filarial nematode
Acanthocheilonema viteae, can suppress ANA pro-
duction and consequent kidney damage in the
MRL/Lpr model of SLE4 by partially downregulat-
ing myeloid differentiation factor 88 (MyD88) in B
cells and kidney cells to reset the regulatory:effector
B cell balance and desensitize renal effector
function.4
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However, the use of living pathogens as therapy
is not ideal and to date, defined parasite-derived
immunomodulators such as ES-62 have not been
exploited as treatments due, for example, to their
inherent problems of immunogenicity. We there-
fore recently designed a library of small drug-like
compounds based around the active phosphoryl-
choline (PC)-moiety of ES-62, and presented
proof of concept that these small molecule ana-
logues (SMAs) provide novel prototypes for devel-
opment of anti-inflammatory drugs for rheumatoid
arthritis.5 We now report that two of these mol-
ecules, the sulfones 11a and 12b, protect against
disease development when administered therapeut-
ically after the onset of kidney damage, in the
MRL/Lpr mouse and also by downregulating
MyD88 levels, with consequent reduction of ANA
and desensitization of kidney effector mechanisms.
Methods
Female MRL/Lpr mice (Harlan-Olac) were main-
tained and assessed for proteinuria (Siemens
Multistix analysis) in accordance with Home
Office Licences PIL60/12183, PIL60/12950,
PPL60/4492 and the ethics review board at the
University of Glasgow.4 Endotoxin-free ES-62
and SMAs 11a, 12b and 19o (Figure 1) were pre-
pared as described previously.5 Following develop-
ment of proteinuria (>1mg/ml), MRL/Lpr mice
were treated twice-weekly with 11a, 12b or 19o
(each at 1mg in 100 ml phosphate-buffered saline
(PBS)) or with PBS alone (100 ml), subcutaneously.
Kidneys were fixed and cryopreserved before
being snap frozen in optimal cutting temperature
(OCT) embedding medium, sectioned (7mm), and
stained with haematoxylin and eosin (H&E) or
periodic acid-Schiff (PAS) before being visualized
(10 and 40 magnification) using an Olympus
BX41 camera. ANA were detected in mouse
serum using human epithelial type 2 (HEp-2)
slides (Antibodies Incorporated, USA) using a
fluorescein isothiocyanate (FITC)-conjugated anti-
mouse immunoglobulin (Ig)G antibody (Vector,
USA) and visualized using an Axiovert fluorescent
microscope at an original magnification of 63.
ANA levels in individual mice were determined by
endpoint dilution analysis.4 Single kidney cell sus-
pensions and supernatants were harvested and
bone marrow-derived macrophages (bmM) differ-
entiated in vitro before being analysed for cytokine
production by enzyme-linked immunosorbent
assay (ELISA) and MyD88 expression by flow
cytometry and Western blotting (25 mg/sample;
quantitative analysis by Image J software) as
described previously.4,5 For flow cytometry, cells
were fixed, permeabilized and stained for intracel-
lular MyD88 using a rabbit anti-mouse-MyD88
antibody (Abcam) followed by an FITC-
conjugated goat-anti-rabbit-antibody (Vector
laboratories).4,5
Statistical analysis of proteinuria was by two-
way analysis of variance (ANOVA) (Bonferroni’s
post-test) whilst all other data were analysed by
one-tailed Student’s t-test.
Results
Therapeutic administration of 11a and 12b
suppresses proteinuria in the MRL/Lpr mouse
A screen of drug-like SMAs based on the immuno-
modulatory PC-moiety of ES-62 identified 11a
and 12b as mimicking the ability of the para-
site product5 to suppress the Toll-like receptor
(TLR)-mediated production of cytokines that pro-
mote the IL-17/IL-22 inflammatory axis which has
been implicated in the pathogenesis of autoimmune
diseases, including lupus.4,5 Thus, the therapeutic
potential of 11a and 12b, relative to PBS and 19o,
a structurally related inactive SMA,5 was assessed
by twice-weekly administration (1 mg/dose) follow-
ing onset of detectable proteinuria (>1mg/ml; week
16) in female MRL/Lpr mice. Examination of the
data generated revealed that treatment with 11a
or 12b, but not 19o, suppressed proteinuria
(Figure 2(a)). However, all of the 12b-treated
mice developed some proteinuria (3mg/ml; data
not shown) and neither SMA prevented glomerular
hypercellularity (Figure 2(b)). Nevertheless,
Figure 1 Structures of SMAs 11a, 12b and 19o.
SMAs: small molecule analogues.
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protection against proteinuria was associated with
reductions in cellular infiltration of the kidney and
ANA production (Figure 2(b)–(d)).
Mechanism of SMA action
As with protection afforded by ES-62,4 both SMA
11a and 12b induced downregulation of MyD88
expression by kidney cells (Figure 3(a)).
Moreover, when we analysed the levels of MyD88
in bmM derived from MRL/Lpr mice, as a surro-
gate for the inflammatory M1-like macrophages
infiltrating the kidney during active lupus, it was
found that in vitro treatment with 11a and 12b
(1 and 5 mg/ml), but not 19o (results not shown),
reduced the steady-state (to a comparable extent as
ES-62; Figure 3(b)) and lipopolysaccharide
(LPS)-upregulated levels of MyD88 in bmM
(Figure 3(c)). Moreover, this 11a and 12b-mediated
downregulation of MyD88 was associated with
inhibition of LPS-mediated pro-inflammatory
interleukin (IL)-6 responses (Figure 3(d)). Finally,
analysis of the kidney supernatants4 of mice treated
with 11a and 12b revealed that the protection
afforded by the SMAs was associated with reduced
levels of IL-6 (Figure 3(e)).
Figure 2 SMAs 11a and 12b, but not 19o, suppress proteinuria and ANA when administered therapeutically. (a) SMAs 11a, 12b,
19o, and PBS were administered following development of proteinuria (>1mg/ml; arrow). Data presented are mean proteinuria
scores SEM where n¼ 6 mice for all groups, except 19o where n¼ 2 and bars indicate range. (b) H&E and PAS staining of kidney
sections from mice (after 22 weeks) treated with PBS, 11a or 12b at the indicated magnification with digital zoom images of
glomeruli incorporating 100 mm scale bars. (c) Representative images of ANA staining of HEp-2 slides using the indicated serum
dilutions from PBS-, 11a- or 12b-treated mice with ANA levels in individual mice shown in (d). SMAs: small molecule analogues;
ANA: antinuclear antibodies; PBS: phosphate-buffered saline; HEp-2: human epithelial type 2; H&E: haematoxylin and eosin;
PAS: periodic acid-Schiff.
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Discussion
SMAs 11a and 12b suppress the development of
proteinuria in the MRL/Lpr mouse, even after the
onset of pathology, suggesting that SMAs such as
these may have therapeutic potential in SLE.
Indeed, the relevance of their therapeutic action is
highlighted by reports that MyD88 signalling is
essential for pathogenesis in the MRL/Lpr
Figure 3 SMAs 11a and 12b suppress MyD88 signalling and downstream effector IL-6 responses in the kidney. (a) Flow
cytometric analysis (MFI) of kidney MyD88 expression in individual mice (week 22). (b) MyD88 expression by bmM5 stimulated
with LPS (1 mg/ml), ES-62 (2 mg/ml), 11a or 12b (both at 1 and 5mg/ml) for 18 hours: exemplar Western blot and quantitation of
MyD88/b-actin expression normalized to the ‘None’ (medium) control. (c) Flow cytometric analysis of MyD88 expression by bmM
treated with 11a or 12b (5 mg/ml, two hours) prior to stimulation with LPS for 18 hours. IL-6 release by these cells (d), and in the
kidney supernatants of PBS-, 11a- or 12b-treated (1 mg/dose) MRL/Lpr mice (e). SMAs: small molecule analogues; MFI: mean
fluorescence intensity; LPS: lipopolysaccharide; IL-6: interleukin-6; PBS: phosphate-buffered saline; bmM: bone marrow-derived
macrophages; MyD88: myeloid differentiation factor 88.
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mouse,6 in particular by promoting the generation
of interferon (IFN)a, IL-6 and ANAs required to
drive autoimmune renal disease.6,7 Dissection of
the pathogenic roles of MyD88 has indicated that
deficiency solely in B cells is sufficient to protect
against nephritis in both the MRL/Lpr and
Lyn–/– mouse models of lupus,8,9 as MyD88 signal-
ling is essential for ANA production, activation of
nephrotoxic T cells and glomerulonephritis.
Reflecting this, ES-62 suppresses production of
each of IL-6þ B cells, plasmablasts and ANA in
MRL/Lpr mice and its desensitization of hyper-
responsive B cells is associated with downregula-
tion of their MyD88 expression and accompanied
by an increased capacity of such B cells to express
FcgRIIb, which mediates negative feedback regula-
tion by immune complexes, and also produce the
regulatory cytokine, IL-10.4 Indeed, the ability of
splenic B cells from ES-62-treated MRL/Lpr mice
to suppress lupus nephritis in recipient animals
underlines the importance of downregulation of
MyD88 expression in the ES-62-mediated resetting
of the effector:regulatory B cell balance.4
Consistent with these findings in experimental
models, MyD88 is required for the activation of
antibody-producing plasma cells in patients10 and
hence, together with its role in TLR/IL-1R signal-
ling, has been identified as a therapeutic target in
SLE.11 Moreover, given that ES-62 downregulates
expression of MyD88 during IL-1-mediated induc-
tion of T helper (Th)17 cells12 and that there is
evidence from studies on SLE patients that effector
T cells are refractory to modulation by regulatory
T cells (Tregs),13 recent findings suggesting that
IL-1R-MyD88 signalling renders naive CD4þ
T cells refractory to Tregs to allow Th1/Th17 dif-
ferentiation14 provide an additional mechanism for
suppressing lupus pathogenesis by targeting
MyD88.
Like ES-62,4 SMA 11a and 12b act to maintain
renal filter barrier and kidney functionality, as indi-
cated by the significantly lower levels of proteinuria
observed in treated mice, despite not inducing a
global improvement in kidney histopathology.
Rather, given its likely central role in integrating
pathogenic crosstalk amongst TLR, complement
and Fc receptors in SLE, this protection may be
explained by the downregulation of MyD88 render-
ing renal cells hyporesponsive to such proinflam-
matory stimuli. This hypothesis is supported by
the suppressed production of IL-6 by renal cells
from MRL/Lpr mice exposed to 11a or 12b, the
importance of which is reflected by the recent off-
label success of IL-6-targeting biologics (anti-IL-6R
monoclonal antibody (mAb), tocilizumab) in SLE
patients, as well as the current phase II trials with
anti-IL-6 mAbs in lupus nephritis (sirukumab) and
in a randomized clinical trial (RCT) in SLE
(PF-04236921).1 Moreover, whilst ES-62 selectively
suppresses infiltration of the kidney by inflamma-
tory T cells, neutrophils and M1-like macrophages,
it increases the levels of tissue-protective M2-like
macrophages that are deficient in lupus.4
Intriguingly, therefore, given that ES-62 and
SMA 11a and 12b all downregulate MyD88 and
IL-6 expression by kidney cells in vivo, and their
inhibition of LPS-stimulated release of IL-6 by
bmM derived from MRL/Lpr mice is associated
with reduced MyD88 expression, it has recently
been reported that deletion of MyD88 in endo-
thelial and myeloid cells results in reduced recruit-
ment of M1-like inflammatory macrophages, and
abrogation of the pathogenic phenotypic switch
from protective M2- to pathogenic M1-like macro-
phages in adipose tissue, in an obesity-related
model of inflammatory disease.15
Perhaps surprisingly given their relative poten-
cies in suppressing proteinuria in MRL/Lpr mice,
SMA 12b was more effective than 11a in suppress-
ing TLR4-mediated IL-6 production by bmM
in vitro. However, it should be noted that the
data obtained in vivo might be influenced by differ-
ences in the pharmacokinetics of the two SMAs.
Nevertheless, our findings indicate SMA 11a to be
the more effective at suppressing proteinuria.
By resetting the level of MyD88 signalling in both
infiltrating and resident kidney cells, SMAs such as
11a appear to act to suppress generation of patho-
genic ANA and consequent immune complex-
deposition and pro-inflammatory cell infiltration,
responses which in concert drive IL-6-mediated
lupus nephritis.7 Thus, such a drug-like compound,
based on the safe, natural immunomodulatory
action of ES-62 that has evolved over millennia to
suppress aberrant, but not protective, inflamma-
tion, may provide the starting point for the devel-
opment of novel therapies for SLE.
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